2024
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd pointsThe survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapyComparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.
Matteson K, Nassar A, Ellis-Caleo T, Mingo E, Aggarwal V, Sridhar A, Alam S, Crowley F, Aboubakar Nana F, Ahmed M, Grohe C, Zurera Berjaga M, Pinato D, Watson A, Chiang A, Naqash A. Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study. Journal Of Clinical Oncology 2024, 42: 8602-8602. DOI: 10.1200/jco.2024.42.16_suppl.8602.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsFirst-line treatmentMedian progression-free survivalOverall survivalChemo-immunotherapyMedian OSLung cancerAll-grade treatment-related adverse eventsRare subtype of lung cancerMulti-institutional retrospective analysisSmall cell lung cancerCell neuroendocrine carcinomaInternational retrospective studyCell lung cancerSubtype of lung cancerLog-rank testFeatures of adenocarcinomaOptimal treatment approachClinical trial dataChemo-regimensNeuroendocrine carcinomaChemo groupSystemic therapyRare subtype
2023
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
Nassar A, Adib E, Feng J, Aredo J, Parikh K, Harris J, Velazquez Manana A, Ragavan M, Lin J, Piotrowska Z, Fitzgerald B, Grohé C, Sankar K, Neal J, Wakelee H, Shepherd F, Herbst R, Naqash A, Goldberg S, Kim S. EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC). Journal Of Clinical Oncology 2023, 41: 8567-8567. DOI: 10.1200/jco.2023.41.16_suppl.8567.Peer-Reviewed Original ResearchEGFR tyrosine kinase inhibitorsDisease-free survivalTyrosine kinase inhibitorsTreatment-related adverse eventsConcurrent chemoradiationOverall survivalStage IIILonger disease-free survivalMulti-institutional retrospective analysisDefinitive radiation therapyPD-L1 expressionPD-L1 statusDefinitive concurrent chemoradiationEGFR-TKI therapyPlatinum-based chemotherapyCell lung cancerEGFR-mutant NSCLCGy of radiationAdjuvant osimertinibCTCAE 5.0PACIFIC trialAdvanced NSCLCConcurrent chemotherapyBaseline characteristicsMedian duration
2021
Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis
Przespolewski A, Goldberg A, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, Waksal J, Ball B, Famulare C, Stahl M, Mckinnell Z, Baron J, Griffiths E, Thompson J, Sweet K, Wang E. Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis. Blood 2021, 138: 1264. DOI: 10.1182/blood-2021-153791.Peer-Reviewed Original ResearchEntity's Board of DirectorsSecondary acute myeloid leukemiaCPX-351Overall survivalS-AMLAcute myeloid leukemiaYounger ptsCancer CenterComprehensive cancer centerAML-MRCComplex karyotypeTP53 mutationsMyeloid leukemiaResponse assessmentAdverse eventsJazz PharmaceuticalsRetrospective analysisClinically significant bleeding eventsDaiichi Sankyo: ConsultancyEfficacy of CPX-351Treated with CPX-351Allogeneic stem cell transplantationMulti-institutional retrospective analysisRetrospective review of clinical experienceRoswell Park Comprehensive Cancer CenterSBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer
Morris L, Viehman J, Baclay J, Chang D, Kerans S, Molitoris J, Regine W, Johung K, Jethwa K, Neibart S, Jabbour S, Hallemeier C. SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e61. DOI: 10.1016/j.ijrobp.2021.07.408.Peer-Reviewed Original ResearchStereotactic body radiation therapyPancreatic ductal adenocarcinomaSurgical resectionFirst recurrenceCumulative incidenceLocal recurrenceDistant metastasisCompletion of SBRTTime of SBRTLow treatment-related toxicityMulti-institutional retrospective analysisDetails of recurrenceGrade 3 toxicityPrior treatment characteristicsInitial surgical resectionR0 resection rateTreatment-related toxicityRisk of progressionIsolated local recurrenceOverall survival estimatesLocal tumor controlSuperior mesenteric arteryBody radiation therapyKaplan-Meier modelOncologic surgical resectionLinear accelerator-based single-fraction stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy for intact and resected brain metastases up to 3 cm: A multi-institutional retrospective analysis.
Diamond BH, Jairam V, Zuberi S, Li JY, Marquis TJ, Rutter CE, Park HS. Linear accelerator-based single-fraction stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy for intact and resected brain metastases up to 3 cm: A multi-institutional retrospective analysis. Journal Of Radiosurgery And SBRT 2021, 7: 179-187. PMID: 33898081, PMCID: PMC8055233.Peer-Reviewed Original ResearchIntracranial progression-free survivalLocal progression-free survivalSingle-fraction stereotactic radiosurgeryProgression-free survivalBrain metastasesSF-SRSOverall survivalStereotactic radiotherapyStereotactic radiosurgeryMulti-institutional retrospective analysisSignificant differencesResected Brain MetastasesLarge brain metastasesTime of treatmentIntact metastasesRetrospective analysisLocal controlMetastasisSimilar outcomesSurvivalPatientsRadiotherapyRadiosurgery
2020
Association of De Ritis Ratio and Neutrophil Lymphocyte Ratio with renal functional decline and all-cause mortality in renal cell carcinoma.
Keiner C, Meagher M, Patil D, Saito K, Patel D, Ghali F, Dutt R, Miller N, Bradshaw A, Wan F, Yasuda Y, Fuji Y, Master V, Derweesh I. Association of De Ritis Ratio and Neutrophil Lymphocyte Ratio with renal functional decline and all-cause mortality in renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 741-741. DOI: 10.1200/jco.2020.38.6_suppl.741.Peer-Reviewed Original ResearchNeutrophil-lymphocyte ratioPlatelet-lymphocyte ratioDe Ritis ratioKaplan-Meier analysisIndependent risk factorMultivariable analysisRenal cell carcinomaRisk factorsCause mortalityCell carcinomaFunctional declinePre-operative neutrophil-lymphocyte ratioElevated neutrophil-lymphocyte ratioMulti-institutional retrospective analysisDe novo CKDRenal functional declineHigh-risk patientsGlomerular filtration rateDe novoWorse OSLymphocyte ratioMale sexTumor sizeBlack raceFiltration rate
2017
SURG-06. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR BRAIN METASTASIS
Sloan A, Tatter S, Mohammadi A, Judy K, Prabhu S, Lovick D, Chamoun R, Chiang V, Leuthardt E. SURG-06. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR BRAIN METASTASIS. Neuro-Oncology 2017, 19: vi236-vi236. PMCID: PMC5693010, DOI: 10.1093/neuonc/nox168.963.Peer-Reviewed Original ResearchBrain metastasesBrain tumorsMedian ECOG performance statusMulti-institutional retrospective analysisECOG performance statusMetastatic brain tumorsMedian survivalPerformance statusMedian ageNeurological deathInoperable tumorsRetrospective databaseTumor locationFrequent primaryRetrospective analysisInvasive proceduresAlternative treatmentPatientsDischarge statusMetastasisGliomasPrevious treatmentLaser interstitial thermotherapyTumorsTreatmentSURG-21. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMAS (GBMS)
Sloan A, Tatter S, Mohammadi A, Judy K, Prabhu S, Lovick D, Chamoun R, Chiang V, Leuthardt E. SURG-21. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMAS (GBMS). Neuro-Oncology 2017, 19: vi239-vi240. PMCID: PMC5693007, DOI: 10.1093/neuonc/nox168.977.Peer-Reviewed Original ResearchRecurrent GBMLaser interstitial thermotherapyRecurrent glioblastomaMulti-institutional retrospective analysisMedian ICU stayMedian overall survivalMedian patient ageTime of diagnosisLarger median volumeECOG statusICU stayConsecutive patientsOverall survivalPatient ageUnresectable tumorsRetrospective seriesMale genderTotal stayMedian volumeRetrospective analysisInvasive proceduresOutcome differencesBrain tumorsNewly DiagnosedPatientsStereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control
An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy And Oncology 2017, 125: 80-88. PMID: 28916225, DOI: 10.1016/j.radonc.2017.08.009.Peer-Reviewed Original ResearchConceptsIntracranial disease controlNew brain metastasesIntracranial controlStereotactic radiosurgeryBrain metastasesOverall survivalDisease controlLymphocyte countMulti-institutional retrospective analysisYale-New Haven HospitalMD Anderson cohortMelanoma brain metastasesAbsolute lymphocyte countAntitumor immune responseImmune checkpoint blockadeMetastatic melanoma patientsComplete blood countTumor-specific antigensIndependent validation cohortMulti-institutional studyIpilimumab therapyMedian followLast doseCheckpoint blockadeIntracranial recurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply